Physician

Navid Ezra, M.D.

According to 2025 Medicare claims, Navid Ezra, M.D. (NPI: 1104110071) practices dermatology in the Yuma, AZ market, with the plurality of this provider's patient population coming from Yuma, AZ. This provider's primary affiliated billing organization is CALIFORNIA DERMATOLOGY INSTITUTE PC (NPI: 1235671389; TIN: 472698023) and primary practice location at 85364-9998.

Ezra's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 2,187 traditional Medicare patients, billed 13,905 HCPCS/CPT codes, and received $2,345,817 in Medicare payments. The top billing code was 17004 (Destruction of precancer skin growth, 15 or more growths). Part D data shows 9,418 prescription claims across 1,791 beneficiaries totaling $4,114,726 in drug costs, led by Tacrolimus (Tacrolimus). 2021 DME data shows 48 claims. Open Payments data shows 320 records totaling $2,122,010. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $511 to $2,345,817. Similarly, Part D prescription costs have moved sharply higher in recent years, from $58,842 to $4,114,726. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	N/R	N/R	N/R
2016	11	17	$511
2017	129	749	$73,663
2018	200	4,400	$289,088
2019	447	67,585	$891,216
2020	539	81,201	$973,173
2021	703	49,148	$908,115
2022	1,259	24,704	$1,442,879
2023	1,873	16,772	$1,811,085
2024	2,187	13,905	$2,345,817

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	255	402	$58,842
2016	636	1,406	$391,459
2017	433	1,082	$505,649
2018	368	1,771	$958,834
2019	585	3,292	$1,378,030
2020	644	3,847	$1,881,001
2021	915	4,184	$1,805,309
2022	1,553	7,186	$3,116,654
2023	2,220	9,143	$3,844,071
2024	1,791	9,418	$4,114,726

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	110	138	$74,529
2019	106	144	$73,069
2020	68	76	$34,093
2021	46	48	$20,633
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
17004	Destruction of precancer skin growth, 15 or more growths	398	698	$143
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	749	1,399	$100
17110	Destruction of skin growth, 1-14 growths	546	978	$93
99203	New patient office or other outpatient visit with low level of medical decision making, if using time, 30 minutes or more	406	406	$75
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	695	1,164	$68

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Tacrolimus	Tacrolimus	1,195	39,013	$470,520
Amcinonide	Amcinonide	116	3,510	$382,069
Otezla	Apremilast	77	2,296	$363,856
Lofena	Diclofenac Potassium	146	4,380	$340,191
Diflorasone Diacetate	Diflorasone Diacetate	420	12,710	$263,564

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	119	$119,209	ABBVIE INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	201	$2,002,802	Takeda Pharmaceuticals U.S.A., Inc.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Navid Ezra, M.D.?

Tedicare shows public-source Medicare data for Navid Ezra, M.D. (NPI 1104110071), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Navid Ezra, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Navid Ezra, M.D.?

Navid Ezra, M.D. is linked to CALIFORNIA DERMATOLOGY INSTITUTE PC (billing NPI 1235671389) in the available physician profile data.

Does Navid Ezra, M.D. have Open Payments data?

Navid Ezra, M.D. has 320 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.